Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-Guided ACEI vs ARB Selection in Hypertension
NCT05535595Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Nov 2019
- Primary completion
- Aug 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of perindopril and candesartan in hypertension (HTN) (2 arms), sponsored by Yonsei University. Primary endpoints: Incidence of cough at 6 weeks and Incidence of moderate/severe cough at 6 weeks. Started Nov 2019; status: completed.
02
Drugs
perindoprilcandesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05535595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535595.